ORCID Profile
0000-0001-7068-7475
Current Organisation
UNSW Sydney
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS
Date: 30-04-2018
DOI: 10.3906/SAG-1710-71
Abstract: Background/aim: Infertility is a main health issue. The human Y chromosome contains essential genes for spermatogenesis, especially those located on four major intervals defined as AZFa, AZFb, AZFc, and AZFd. A partial deletion of the AZFc region is reported as a significant risk factor for oligo-/azoospermia. The main purpose of this study was to investigate the prevalence of partial deletions in the AZFc region (gr/gr, b1/b3, and b2/b3) in Iranian oligozoospermic candidates for intracytoplasmic sperm injection. Materials and methods: Multiplex PCR was used to assess the micro and partial deletions in 60 oligozoospermia infertile and 80 fertile men. Results: Two cases (3.33%) showed AZFb deletion but no microdeletion was detected in the control s les. In the AZFc region, 20% of the patients showed deletions, in which 15% and 5% showed gr/gr and b2/b3 deletions, respectively. However, 10% of the healthy in iduals also showed partial deletions, including gr/gr (7.5%) and b2/b3 (2.5%). No significant correlation was detected between the presence of gr/gr microdeletion in patients and controls (P > 0.05). Conclusion: Our study showed that the partial AZFc deletions are not associated with male infertility in Iranian subjects.
Publisher: OMICS Publishing Group
Date: 2017
Publisher: Springer Science and Business Media LLC
Date: 08-12-2022
DOI: 10.1038/S41598-022-25360-6
Abstract: Due to the high prevalence and considerable increase of prostate cancer, finding novel therapeutic compounds for the treatment of prostatic cancer has been the goal of many researches. In this study, we aimed to fabricate the Bismuth oxide (Bi 2 O 3 ) NPs, functionalized with glutamine (Gln) and conjugated with Thiosemicarbazide (TSC). Then, the anticancer mechanism of the synthesized NPs was investigated using the cellular and molecular tests including MTT assay, Flow cytometry, Caspase-3 activity assay, Hoechst staining and Real Time PCR. The FT-IR and XRD assays confirmed the identity of the synthesized Bi 2 O 3 /Gln-TSC NPs. The size range of the synthesized spherical particles was 10–60 nm and the zeta potential was − 23.8 mV. The purity of the NPs was confirmed by EDX-mapping analysis. The Bi 2 O 3 /Gln-TSC was considerably more toxic for prostate cancer cells than normal human cells and the IC 50 was calculated 35.4 and 305 µg/mL, respectively. The exposure to the NPs significantly increased the frequency of apoptotic cells from 4.7 to 75.3%. Moreover, the expression of the CASP8 , BAX , and Bcl-2 genes after exposure to the NPs increased by 2.8, 2.3, and 1.39 folds. Treating the cancer cells with Bi 2 O 3 /Gln-TSC increased the activity of the Caspase-3 protein and apoptotic morphological features were observed by Hoechst staining in the treated cells. This work showed that Bi 2 O 3 /Gln-TSC has considerable cytotoxicity for prostate cancer cells and could inducing both intrinsic and extrinsic pathways of apoptosis.
Publisher: OMICS Publishing Group
Date: 2017
Publisher: The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS
Date: 30-04-2018
DOI: 10.3906/SAG-1710-71
Abstract: Background/aim: Infertility is a main health issue. The human Y chromosome contains essential genes for spermatogenesis, especially those located on four major intervals defined as AZFa, AZFb, AZFc, and AZFd. A partial deletion of the AZFc region is reported as a significant risk factor for oligo-/azoospermia. The main purpose of this study was to investigate the prevalence of partial deletions in the AZFc region (gr/gr, b1/b3, and b2/b3) in Iranian oligozoospermic candidates for intracytoplasmic sperm injection. Materials and methods: Multiplex PCR was used to assess the micro and partial deletions in 60 oligozoospermia infertile and 80 fertile men. Results: Two cases (3.33%) showed AZFb deletion but no microdeletion was detected in the control s les. In the AZFc region, 20% of the patients showed deletions, in which 15% and 5% showed gr/gr and b2/b3 deletions, respectively. However, 10% of the healthy in iduals also showed partial deletions, including gr/gr (7.5%) and b2/b3 (2.5%). No significant correlation was detected between the presence of gr/gr microdeletion in patients and controls (P > 0.05). Conclusion: Our study showed that the partial AZFc deletions are not associated with male infertility in Iranian subjects.
Publisher: Elsevier BV
Date: 2022
DOI: 10.1016/J.LFS.2021.120222
Abstract: In order to overcome limitations of conventional cancer therapy methods, immunotoxins with the capability of target-specific action have been designed and evaluated pre-clinically, and some of them are in clinical studies. Targeting cancer cells via antibodies specific for tumour-associated surface proteins is a new biomedical approach that could provide the selectivity that is lacking in conventional cancer therapy methods such as radiotherapy and chemotherapy. A successful ex le of an approved immunotoxin is represented by immunoRNases. ImmunoRNases are fusion proteins in which the toxin has been replaced by a ribonuclease. Conjugation of RNase molecule to monoclonal antibody or antibody fragment was shown to enhance specific cell-killing by several orders of magnitude, both in vitro and in animal models. There are several RNases obtained from different mammalian cells that are expected to be less immunogenic and systemically toxic. In fact, RNases are pro-toxins which become toxic only upon their internalization in target cells mediated by the antibody moiety. The structure and large size of the antibody molecules assembled with the immunoRNases have always been a challenge in the application of immunoRNases as an antitoxin. To overcome this obstacle, we have offered a new strategy for the application of immunoRNases as a promising approach for upgrading immunoRNAses with maximum affinity and high stability in the cell, which can ultimately act as an effective large-scale cancer treatment. In this review, we introduce the optimized antibody-like molecules with small size, approximately 10 kD, which are presumed to significantly enhance RNase activity and be a suitable agent with the potential for anti-cancer functionality. In addition, we also discuss new molecular entities such as monobody, anticalin, nonobody and affilin as refined versions in the development of immunoRNases. These small molecules express their functionality with the suitable small size as well as with low immunogenicity in the cell, as a part of immunoRNases.
No related grants have been discovered for William Dashtmiani.